Laboratory for Pediatric Sarcoma Biology

Startseite
Deutschland
Munich
Laboratory for Pediatric Sarcoma Biology

Translational Research for Pediatric Sarcoma Patients Research outline

Our mission is to improve outcome for children and young adolescents with sarcoma.

We aim at developing novel therapeutic strategies based on new insights into the molecular mechanisms of disease following two major lines of research. Our investigations start with the analysis of the patients’ tumors in situ, followed by studying patient-derived cell lines using a wide variety of in silico, in vitro, and in vivo techniques.

1. Tumorigenesis in the context of developmental pathways:

Dominant oncogenes often hijack or interfere with developmental pathways thereby conferring a considerable growth advantage to tumor cells. We are interested in the mechanisms through which oncogenes arrest sarcoma cells in a lineage-specific, early-committed but yet largely undifferentiated state via deregulation of key developmental pathways, and how they cooperate with them to promote tumorigenesis and cancer progression.

2. Therapy resistance, tumor heterogeneity, and predictive biomarkers:

Primary and/or secondary resistance to conventional chemotherapeutic drugs is a frequent event in pediatric sarcoma. Chemo-resistance is a highly specific process in which tumors become resistant to certain drugs while maintaining (limited) susceptibility toward others. Underlying to this resistance is considerable plasticity due to intra-tumor heterogeneity, which enables the adaptation to therapeutic stress on the clonal and sub-clonal level. We strive for illuminating the genetic basis and biological mechanisms of tumor-heterogeneity and aim at identifying novel biomarkers for individualized risk-stratification, prediction of treatment response, and to indicate which targeted therapeutics may help overcoming resistance to conventional therapeutic drugs.

10/06/2021

proudly presents the ' Cell Line Atlas (ESCLA)' – a multi-omics characterization of 18 cell lines w/wo EWSR1-ETS knockdown. This team effort was mainly funded by
delivering an

Cell lines have been essential for major discoveries in cancer including Ewing sarcoma (EwS). EwS is a highly aggressive pediatric bone or soft-tissue cancer characterized by oncogenic EWSR1-ETS fusion transcription factors converting polymorphic GGAA-microsatellites (mSats) into neo-enhancers. Howe...

15/05/2020

Exited to share our new paper!

We discovered that oncogenic hijacking of a developmental transcription factor evokes vulnerability toward oxidative stress in Ewing sarcoma.

https://www.nature.com/articles/s41467-020-16244-2

23/01/2020

Check out our FREE review in and Reviews: "Targeting the undruggable: exploiting neomorphic features of fusion in childhood for innovative "
https://bit.ly/2RFiQ0c

Great work by Max Knott,
, et al

While sarcomas account for approximately 1% of malignant tumors of adults, they are particularly more common in children and adolescents affected by cancer. In contrast to malignancies that occur in...

30/12/2019

Interested in interdisciplinary and collaborative sarcoma research?

Please consider to register for the EuSARC 2020 conference 'The biology of sarcoma - from basic mechanisms to innovative therapies'!

The EuSARC 2020 conference will take place from June 4th to June 6th in wonderful Pamplona, Spain.

https://eusarc.com

28/12/2019

Hippo pathway effectors YAP1/TAZ induce an EWS‐FLI1‐opposing gene signature and associate with disease progression in Ewing sarcoma

Congratulations to our co-frist author Dr. Laura Romero-Pérez

17/11/2019

📣Check our NEW paper :
Integrative transcriptome analysis reveals TMPRSS2‐ERG dependency of prognostic in

👉https://t.co/FgJzG4oqPt

Great collboration of

In prostate adenocarcinoma (PCa), distinction between indolent and aggressive disease is challenging. Around 50% of PCa are characterized by TMPRSS2‐ERG (T2E)‐fusion oncoproteins defining two molecul...

11/09/2019

Our new paper is out!

https://www.nature.com/articles/s41467-019-12071-2

We discovered that cooperation of cancer drivers with regulatory germline variants shapes clinical outcomes.

See our graphical abstract below!

31/07/2019

Our NEW review on STAG mutations in cancer is up

https://bit.ly/2Yd2emJ

Great collaboration with of
with Institut Curie and Institut Imagine

Stromal Antigen 1 and 2 (STAG1/2) are key subunits of the cohesin complex that mediate sister chromatid cohesion, DNA repair, transcriptional regulation, and genome topology. Genetic alterations comprising any of the 11 cohesin-associated genes possibly occur in up to 26% of patients included in The...

16/07/2019

NEW review

Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours

Paediatric solid tumours are known to be divergent from adult malignancies. This Review describes the molecular landscape of paediatric solid tumours, the therapeutic vulnerabilities that can be targeted and the preclinical models available to test the efficacy of investigational drugs with a view t...

09/07/2019

Congratulations to our MD thesis student Merve Kasan, who was awarded with a Mildred-Scheel doctoral scholarship from the German Cancer Aid for her project on evolution of

“Congratulations to our MD thesis student Merve Kasan, who was awarded with a Mildred-Scheel doctoral scholarship from the German Cancer Aid for her project on evolution of ”

28/03/2019

🔥 Check out our NEW preprint! 🔥

Hippo pathway effectors YAP1/TAZ induce a EWS-FLI1-opposing gene signature and associate with disease progression in Ewing sarcoma

YAP1 and TAZ (WWTR1) oncoproteins are the final transducers of Hippo tumor suppressor pathway. Deregulation of the pathway leads to YAP1/TAZ activation fostering tumorigenesis in multiple malignant tumor types, including sarcoma. However, oncogenic mutations within the core components of the Hippo p...

15/03/2019

🔥 Our NEW preprint is out 🔥

Oncogenic hijacking of a developmental transcription factor evokes therapeutic vulnerability for ROS-induction in Ewing sarcoma

https://www.biorxiv.org/content/10.1101/578666v1

Congratulations to all involved, and especially to Aruna!!

Adresse

Thalkirchner Str. 36
Munich
80337

Telefon

+4989218073716

Webseite

http://www.pathologie.med.uni-muenchen.de/020wissenschaft/ag_gruenewald/index.html

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von Laboratory for Pediatric Sarcoma Biology erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.